Mariner LLC Sells 31,948 Shares of Envista Holdings Co. (NYSE:NVST)

Mariner LLC decreased its holdings in Envista Holdings Co. (NYSE:NVST - Free Report) by 23.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102,919 shares of the company's stock after selling 31,948 shares during the quarter. Mariner LLC owned approximately 0.06% of Envista worth $1,985,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC raised its position in shares of Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after purchasing an additional 1,638 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after buying an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Envista during the 4th quarter worth approximately $53,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Envista in the fourth quarter valued at about $86,000. Finally, KBC Group NV raised its holdings in shares of Envista by 63.9% during the 4th quarter. KBC Group NV now owns 7,903 shares of the company's stock valued at $152,000 after purchasing an additional 3,082 shares in the last quarter.

Analysts Set New Price Targets

NVST has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered their price objective on shares of Envista from $20.00 to $19.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Piper Sandler raised their price target on Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Jefferies Financial Group upped their price objective on Envista from $20.00 to $22.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. New Street Research set a $19.00 price target on shares of Envista in a report on Thursday, March 6th. Finally, UBS Group cut their price target on shares of Envista from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Monday, March 10th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $19.96.

Envista Stock Performance

Shares of NVST traded up $0.03 during trading hours on Tuesday, hitting $15.99. The company had a trading volume of 140,221 shares, compared to its average volume of 2,499,251. The business has a fifty day moving average of $17.10 and a 200-day moving average of $19.10. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The firm has a market cap of $2.71 billion, a price-to-earnings ratio of -2.46, a PEG ratio of 1.27 and a beta of 1.12. Envista Holdings Co. has a 12 month low of $14.22 and a 12 month high of $23.00.

Envista (NYSE:NVST - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities analysts anticipate that Envista Holdings Co. will post 1 EPS for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.